Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

A multi-centric study on the efficacy of eltrombopag in management of refractory chronic immune thrombocytopenia

Cekdemir D, Guvenc S, Ozdemirkiran F, Eser A, Toptas T, Ozkocaman V, Haydaroglu Sahin H, Ermis Turak E, Esen R, Comert M, Sadri S, Aslaner M, Uncu Ulu B, Karakus A, Selim Bapur D, Alacacioglu I, Aydin D, Tekinalp A, Namdaroglu S, Ceran F, Tarkun P, Kiper D, Cetiner M, Yenerel M, Demir AM, Yilmaz G, Terzi H, Atilla E, Malkan UY, Acar K, Ozturk E, Tombak A, Sunu C, Salim O, Alayvaz N, Sayan O, Ozan U, Ayer M, Gokgoz Z, Andic N, Kizilkilic E, Noyan F, Ozen M, Pepedil Tanrikulu F, Alanoglu G, Ozkan HA, Aslan V, Cetin G, Akyol Erikci A, Deveci B, Ersoy Dursun F, Dermenci H, Aytan P, Gunduz M, Karakus V, Ozlu C, Demircioglu S, Akay Yanar OM, Ozatli D, Undar L, Tiftik EN, Turkoz Sucak AG, Haznedaroglu I, Ozcan M, Sencan M, Tombuloglu M, Ozet G, Bilgir O, Turgut B, Ozcan MA, Payzın KB, Sonmez M, Ayyildiz O, Dal MS, Ertop S, Turgut M, Soysal T, Kaya E, Unal A, Pehlivan M, Atagunduz I, Tuglular Firatli T, Saydam G, Diz Kucukkaya R.

Turk J Haematol. 2019 Jul 22. doi: 10.4274/tjh.galenos.2019.2018.0307. [Epub ahead of print]

2.

A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome.

Beksac M, Cengiz Seval G, Kanellias N, Coriu D, Rosiñol L, Ozet G, Goranova-Marinova V, Unal A, Bila J, Ozsan H, Ivanaj A, Balić LI, Kastritis E, Bladé J, Dimopoulos MA.

Haematologica. 2019 Jul 5. pii: haematol.2019.219295. doi: 10.3324/haematol.2019.219295. [Epub ahead of print]

3.

The Turkish experience with therapeutic plasma exchange: A national survey.

Korkmaz S, Solmaz Medeni S, Demirkan F, Kalayoglu Besisik S, Altay Dadin S, Akgun Cagliyan G, Kabukcu Hacioglu S, Sari I, Goren Sahin D, Arat M, Dagdas S, Ozet G, Kutlu N, Karaagac Akyol T, Ozcebe OI, Uskudar Teke H, Kiper Unal D, Guner N, Tombak A, Celik H, Bay I, Kiki I, Ozgur G, Erkurt MA, Ozatli D, Meletli O, Demircioglu S, Demir C, Kurtoglu E, Vural F, Tobu M, Karakus A, Ayyildiz O, Dal MS, Afacan Ozturk B, Albayrak M, Ocakci S, Bolaman Z, Sonmez M, Karakus V, Gokmen Sevindik O, Berber I, Dogu MH, Gulturk E, Ulas T, Payzin B, Kuku I, Cagirgan S, Altuntas F.

Transfus Apher Sci. 2019 Jun;58(3):287-292. doi: 10.1016/j.transci.2019.04.015. Epub 2019 Apr 23. Review.

PMID:
31036516
4.

Biological variation of peripheral blood T-lymphocytes.

Falay M, Senes M, Korkmaz S, Zararsız G, Turhan T, Okay M, Yücel Ç, Kılınckaya MF, Ozet G, Yucel D.

J Immunol Methods. 2019 Jul;470:1-5. doi: 10.1016/j.jim.2019.04.002. Epub 2019 Apr 26.

PMID:
31022389
5.

CD81 Expression in the Differential Diagnosis of Chronic Lymphocytic Leukemia.

Afacan-Öztürk HB, Falay M, Albayrak M, Yıldız A, Öztürk ҪP, Maral S, Özet G.

Clin Lab. 2019 Mar 1;65(3). doi: 10.7754/Clin.Lab.2018.180802.

PMID:
30868852
6.

Hepatitis B Reactivation Rate Is Higher Undergoing Some Cytotoxic Chemotherapy in Patients with Solid Tumors: A Large Retrospective Study.

Karaca M, Tural D, Akar E, Çil İ, Bayrak S, Ozet G, Yucel OK, Hocaoglu E, Ozet A.

Chemotherapy. 2018;63(5):247-252. doi: 10.1159/000489789. Epub 2018 Nov 8.

PMID:
30408779
7.

Hepatitis B and C rates are significantly increased in certain solid tumors: A large retrospective study.

Kocoglu H, Karaca M, Tural D, Hocaoglu E, Okuturlar Y, Fetullahoglu Z, Gunaldi M, Ciftci R, Tuna S, Yucil OK, Yuce OK, Ozet G, Ozet A, Benekli M.

J Cancer Res Ther. 2018 Sep;14:S774-S778. doi: 10.4103/0973-1482.174544. Erratum in: J Cancer Res Ther. 2018 Oct-Dec;14(6):1451. Yuce OK [corrected to Yucil OK].

8.

RS sample: Can be guide for empirical treatment of haematological malignancy patients?

Kaskatepe B, Yildiz SS, Mumcuoglu I, Ozet G, Altuntas EG.

Microb Pathog. 2018 Dec;125:164-167. doi: 10.1016/j.micpath.2018.09.013. Epub 2018 Sep 8.

PMID:
30205194
9.

Biological variation estimates of prothrombin time, activated partial thromboplastin time, and fibrinogen in 28 healthy individuals.

Falay M, Senes M, Korkmaz S, Turhan T, Okay M, Öztürk BA, Yücel D, Ozet G.

Int J Lab Hematol. 2018 Dec;40(6):721-725. doi: 10.1111/ijlh.12910. Epub 2018 Aug 20.

PMID:
30125477
10.

Both Granulocytic and Non-Granulocytic Blood Cells Are Affected in Patients with Severe Congenital Neutropenia and Their Non-Neutropenic Family Members: An Evaluation of Morphology, Function, and Cell Death

Olcay L, Ünal Ş, Onay H, Erdemli E, Öztürk A, Billur D, Metin A, Okur H, Yıldırmak Y, Büyükaşık Y, İkincioğulları A, Falay M, Özet G, Yetgin S.

Turk J Haematol. 2018 Nov 13;35(4):229-259. doi: 10.4274/tjh.2017.0160. Epub 2018 Jul 24.

11.

A multicenter experience of thrombotic microangiopathies in Turkey: The Turkish Hematology Research and Education Group (ThREG)-TMA01 study.

Tekgündüz E, Yılmaz M, Erkurt MA, Kiki I, Kaya AH, Kaynar L, Alacacioglu I, Cetin G, Ozarslan I, Kuku I, Sincan G, Salim O, Namdaroglu S, Karakus A, Karakus V, Altuntas F, Sari I, Ozet G, Aydogdu I, Okan V, Kaya E, Yildirim R, Yildizhan E, Ozgur G, Ozcebe OI, Payzin B, Akpinar S, Demirkan F.

Transfus Apher Sci. 2018 Feb;57(1):27-30. doi: 10.1016/j.transci.2018.02.012. Epub 2018 Feb 20.

PMID:
29503132
12.

What should be the laboratory approach against isolated prolongation of a activated partial thromboplastin time?

Falay M, Senes M, Yücel D, Turhan T, Dagdaş S, Pekin M, Nazaroglu NK, Özet G.

J Clin Lab Anal. 2018 Feb 27. doi: 10.1002/jcla.22415. [Epub ahead of print]

PMID:
29484705
13.

Immunophenotyping of Chronic Lymphocytic Leukemia.

Falay M, Özet G.

Clin Lab. 2017 Oct 1;63(10):1621-1626. doi: 10.7754/Clin.Lab.2017.170406.

PMID:
29035453
14.

Investigation of an algorithm for anti HCV EIA reactivity in blood donor screening in Turkey in the absence of nucleic acid amplification screening.

Karakoc AE, Berkem R, Irmak H, Demiroz AP, Yenicesu I, Ertugrul N, Arslan Ö, Kemahli S, Yilmaz S, Ozcebe O, Kara A, Ozet G, Acikgoz ZC, Acikgoz T.

Transfus Apher Sci. 2017 Oct;56(5):732-737. doi: 10.1016/j.transci.2017.08.025. Epub 2017 Sep 8.

PMID:
28941882
15.

Evaluation of Lymphoma Patients Receiving High-Dose Therapy and Autologous Stem Cell Transplantation: Experience of a Single Center.

Bozkaya Y, Uncu D, Dağdaş S, Erdem GU, Doğan M, Özet G, Zengin N.

Indian J Hematol Blood Transfus. 2017 Sep;33(3):361-369. doi: 10.1007/s12288-016-0756-x. Epub 2016 Nov 29.

16.

The Role of CD200 and CD43 Expression in Differential Diagnosis between Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma.

Falay M, Afacan Öztürk B, Güneş K, Kalpakçı Y, Dağdaş S, Ceran F, Özet G.

Turk J Haematol. 2018 May 25;35(2):94-98. doi: 10.4274/tjh.2017.0085. Epub 2017 Jul 17.

17.

The Assessment of CD56 and CD117 Expressions at the Time of the Diagnosis in Multiple Myeloma Patients.

Ceran F, Falay M, Dağdaş S, Özet G.

Turk J Haematol. 2017 Aug 2;34(3):226-232. doi: 10.4274/tjh.2016.0394. Epub 2017 Mar 8.

18.

CD38 Expression and Variation as a Prognostic Factor Chronic Lymphocytic Leukemia.

Falay M, Ceran F, Gunes AK, Dagdas S, Ayli M, Ozet G.

Clin Lab. 2016 Jul 1;62(7):1287-1293. doi: 10.7754/Clin.Lab.2015.151125.

PMID:
28164634
19.

Combined factor V and VIII deficiency in a young woman with abundant bleeding after tooth extraction.

Ates I, Kaplan M, Tokgoz G, Ceran F, Akalın S, Ozet G.

Blood Res. 2016 Mar;51(1):67-8. doi: 10.5045/br.2016.51.1.67. Epub 2016 Mar 25. No abstract available.

20.

Prognostic significance of flow cytometry findings in Turkish adult acute leukemia patients.

Basturk A, Akinci S, Hacibekiroglu T, Guney T, Kutlucan A, Ceran F, Akalin SD, Ozturk SM, Okutan H, Ozet G, Dilek I.

Eur Rev Med Pharmacol Sci. 2015 Sep;19(18):3360-6.

21.

Determination of HLA-G Expression and Evaluation of Its Role as a Prognostic Factor in Chronic Lymphocytic Leukemia.

Ozet G, Falay M, Dagdas S, Ceran F.

J Clin Lab Anal. 2016 Sep;30(5):399-403. doi: 10.1002/jcla.21868. Epub 2015 Aug 24.

PMID:
26303056
22.

High frequency of aspirin resistance in patients with nephrotic syndrome.

Akoglu H, Agbaht K, Piskinpasa S, Falay MY, Dede F, Ozet G, Odabas AR.

Nephrol Dial Transplant. 2012 Apr;27(4):1460-6. doi: 10.1093/ndt/gfr476. Epub 2011 Aug 23.

PMID:
21865214
23.

Hematogones in immune thrombocytopenic purpura: diagnostic implication.

Akyay A, Falay M, Oztürkmen S, Biçakci Z, Tavil B, Ozet G, Olcay L.

Turk J Pediatr. 2011 Mar-Apr;53(2):219-24.

PMID:
21853665
24.

Association of the PTPN22 gene polymorphism with autoantibody positivity in Turkish rheumatoid arthritis patients.

Ates A, Karaaslan Y, Karatayli E, Ertuğrul E, Aksaray S, Türkyilmaz A, Ozet G.

Tissue Antigens. 2011 Jul;78(1):56-9. doi: 10.1111/j.1399-0039.2011.01675.x. Epub 2011 Apr 21.

PMID:
21506938
25.

Serum thrombin activatable fibrinolysis inhibitor levels in patients with newly diagnosed multiple myeloma.

Balcik OS, Albayrak M, Uyar ME, Dagdas S, Yokus O, Ceran F, Cipil H, Kosar A, Ozet G.

Blood Coagul Fibrinolysis. 2011 Jun;22(4):260-3. doi: 10.1097/MBC.0b013e3283442cf9.

PMID:
21297448
26.

Evaluation of 143 cases of immune thrombocytopenic purpura with regards to clinical course and response to treatment.

Albayrak M, Balcik OS, Aki SZ, Gokmen A, Ceran F, Yokus O, Dagdas S, Ayli M, Ozet G.

Eurasian J Med. 2010 Dec;42(3):120-3. doi: 10.5152/eajm.2010.34.

27.

Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.

Beksac M, Haznedar R, Firatli-Tuglular T, Ozdogu H, Aydogdu I, Konuk N, Sucak G, Kaygusuz I, Karakus S, Kaya E, Ali R, Gulbas Z, Ozet G, Goker H, Undar L.

Eur J Haematol. 2011 Jan;86(1):16-22. doi: 10.1111/j.1600-0609.2010.01524.x. Epub 2010 Nov 22.

PMID:
20942865
28.

Role of flow cytometry in multiple myeloma and the prognostic significance of CD87 (uPAR) expression.

Albayrak M, Şahin Balçık Ö, Dağdaş S, Yılmaz M, Ceran F, Yokuş O, Özet G.

Turk J Haematol. 2010 Sep 5;27(3):182-9. doi: 10.5152/tjh.2010.26.

29.

Evaluation of risk factors for thrombophilia in patients with cerebral venous thrombosis.

Yokuş O, Şahin Balçık Ö, Albayrak M, Ceran F, Dağdaş S, Yılmaz M, Özet G.

Turk J Haematol. 2010 Sep 5;27(3):162-7. doi: 10.5152/tjh.2010.23.

30.

A rare extramedullary involvement in myeloma: lung parenchyma and association with unfavorable chromosomal abnormalities.

Şahin Balçık Ö, Albayrak M, Dağdaş S, Ceran F, Özet G, Demirağ F, Yokuş O.

Turk J Haematol. 2010 Jun 5;27(2):109-12. doi: 10.5152/tjh.2010.08.

31.

Coagulopathy parameters in patients with Crimean-Congo hemorrhagic fever and its relation with mortality.

Onguru P, Dagdas S, Bodur H, Yilmaz M, Akinci E, Eren S, Ozet G.

J Clin Lab Anal. 2010;24(3):163-6. doi: 10.1002/jcla.20383.

PMID:
20486197
32.

Risk factors for thrombophilia in young adults presenting with thrombosis.

Yokus O, Albayrak M, Balcik OS, Ceran F, Dagdas S, Yilmaz M, Ozet G.

Int J Hematol. 2009 Dec;90(5):583-590. doi: 10.1007/s12185-009-0447-6. Epub 2009 Nov 25.

PMID:
19937485
33.

Effects of imatinib mesylate on renin-angiotensin system (RAS) activity during the clinical course of chronic myeloid leukaemia.

Sayitoglu M, Haznedaroğlu IC, Hatirnaz O, Erbilgin Y, Aksu S, Koca E, Adiguzel C, Bayik M, Akalin I, Gülbas Z, Akay M, Unal A, Kaynar L, Ovali E, Yilmaz M, Yenerel M, Dagdas S, Ozet G, Ar C, Aydin Y, Soysal T, Durgun B, Ozcebe O, Tukun A, Ilhan O, Ozbek U.

J Int Med Res. 2009 Jul-Aug;37(4):1018-28.

PMID:
19761684
34.

Analysis of lymphocyte subgroups in Crimean-Congo hemorrhagic fever.

Akinci E, Yilmaz M, Bodur H, Ongürü P, Bayazit FN, Erbay A, Ozet G.

Int J Infect Dis. 2009 Sep;13(5):560-3. doi: 10.1016/j.ijid.2008.08.027. Epub 2008 Dec 27.

35.

Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.

Abali H, Urün Y, Oksüzoğlu B, Budakoğlu B, Yildirim N, Güler T, Ozet G, Zengin N.

Cancer Invest. 2008 May;26(4):401-6. doi: 10.1080/07357900701788098.

PMID:
18443961
36.
37.

An unusual case of spontaneous acute tumor lysis syndrome associated with acute lymphoblastic leukemia: a case report and review of the literature.

Akoz AG, Yildirim N, Engin H, Dagdas S, Ozet G, Tekin IO, Ceran F.

Acta Oncol. 2007;46(8):1190-2. Review. No abstract available.

PMID:
17851839
38.

Bilateral proptosis as the initial presentation of systemic nodular lymphocyte predominant Hodgkin lymphoma.

Akoz AG, Dagdas S, Soysal H, Ozet G, Ustun H.

Leuk Lymphoma. 2007 Jul;48(7):1434-6. No abstract available.

PMID:
17613778
39.

Unusual extramedullary hematopoiesis in a patient receiving granulocyte colony-stimulating factor.

Dagdas S, Ozet G, Alanoglu G, Ayli M, Gokmen Akoz A, Erekul S.

Acta Haematol. 2006;116(3):198-202.

PMID:
17016039
40.

The relation between plasminogen activator inhibitor activity and disease activation in acute myeloblastic leukaemia patients.

Yilmaz M, Dagdas S, Aki SZ, Guler N, Akoz AG, Erdin Z, Alanoglu G, Ozet G.

Clin Lab Haematol. 2006 Oct;28(5):313-6.

PMID:
16999721
41.

Plasma levels of thrombin-activatable fibrinolysis inhibitor in primary and secondary thrombocytosis.

Kaftan O, Balcik OS, Cipil H, Ozet G, Bavbek N, Koşar A, Dagdas S.

Clin Appl Thromb Hemost. 2005 Oct;11(4):449-54.

PMID:
16244771
42.

The plateled-derived growth factor level (PDGF) in Hodgkin's disease and non-Hodgkin's lymphoma and its relationship disease activation.

Güler N, Yilmaz S, Ayaz S, Yilmaz M, Aki Z, Dağdaş S, Gökmen A, Ozet G.

Hematology. 2005 Feb;10(1):53-7.

PMID:
16019446
43.

Expression of IFITM1 in chronic myeloid leukemia patients.

Akyerli CB, Beksac M, Holko M, Frevel M, Dalva K, Ozbek U, Soydan E, Ozcan M, Ozet G, Ilhan O, Gürman G, Akan H, Williams BR, Ozçelik T.

Leuk Res. 2005 Mar;29(3):283-6.

PMID:
15661263
44.

[Comparison of the methenamine silver staining, direct fluorescent antibody and nested-polymerase chain reaction methods in the diagnosis of Pneumocystis carinii pneumonia].

Güneş I, Kalkanci A, Kuştimur S, Ergüven S, Ozet G, Ekim N.

Mikrobiyol Bul. 2004 Jan-Apr;38(1-2):105-12. Turkish.

PMID:
15293909
45.

Lamivudine therapy in acute leukemia patients who are hepatitis B surface antigen carriers.

Yilmaz M, Dagdas S, Güler N, Aki SZ, Aköz AG, Özet G, Ayli M, Saritas U.

Hematology. 2003 Dec;8(6):393-6.

PMID:
14668034
46.

Hypercalcemia and Multiple Pathological Fractures in Chronic Lymphocytic Leukaemia: A Case Report.

Alanoğlu G, Dağdaş S, Akı Z, Yağmurlu F, Özet G.

Turk J Haematol. 2003 Sep 5;20(3):167-70.

PMID:
27265576
47.

High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous stem cell transplantation in patients with advanced breast cancer: a retrospective evaluation.

Demirer T, Uysal VA, Ayli M, Genc Y, Ilhan O, Koc H, Dagli M, Arat M, Gunel N, Fen T, Dincer S, Ustael N, Yildiz M, Ustun T, Seyrek E, Ozet G, Muftuoglu O, Akan H.

Bone Marrow Transplant. 2003 May;31(9):755-61.

PMID:
12732881
48.

Monitoring of peripheral blood CD34+ cell counts on the first day of apheresis is highly predictive for efficient CD34+ cell yield.

Demirer T, Ilhan O, Ayli M, Arat M, Dagli M, Ozcan M, Haznedar R, Genc Y, Fen T, Ayyildiz E, Dincer S, Arslan O, Gurman G, Konuk N, Dalva K, Uysal A, Koc H, Ozet G, Akan H.

Ther Apher. 2002 Oct;6(5):384-9.

PMID:
12423534
49.

Extramedullary Presentation of Biclonal IgGk and IgAk Multiple Myeloma.

Alanoğlu G, Özet G, Dalva K, Kuzu I, Erekul S, İlhan O, Beksaç M.

Turk J Haematol. 2002 Sep 5;19(3):421-5.

PMID:
27264980
50.

Influence of post-transplant recombinant human granulocyte colony-stimulating factor administration on peritransplant morbidity in patients undergoing autologous stem cell transplantation.

Demirer T, Ayli M, Dagli M, Haznedar R, Genc Y, Fen T, Dincer S, Unal E, Gunel N, Seyrek E, Ustun T, Ustael N, Yildiz M, Sertkaya D, Ozet G, Muftuoglu O.

Br J Haematol. 2002 Sep;118(4):1104-11.

PMID:
12199792

Supplemental Content

Support Center